158 related articles for article (PubMed ID: 17964916)
1. Treatment of the dyslipidemia of insulin resistance.
Smith DA
Med Clin North Am; 2007 Nov; 91(6):1185-210, x. PubMed ID: 17964916
[TBL] [Abstract][Full Text] [Related]
2. Controversies in dyslipidemias: atheroprevention in diabetes and insulin resistance.
Brinton EA
Ann N Y Acad Sci; 2005 Dec; 1055():159-78. PubMed ID: 16387723
[TBL] [Abstract][Full Text] [Related]
3. Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome.
Mehta A
Postgrad Med; 2010 May; 122(3):61-70. PubMed ID: 20463415
[TBL] [Abstract][Full Text] [Related]
4. The effect of pharmaceutical intervention on lipid profile in polycystic ovary syndrome.
Diamanti-Kandarakis E; Kandaraki E; Christakou C; Panidis D
Obes Rev; 2009 Jul; 10(4):431-41. PubMed ID: 19413702
[TBL] [Abstract][Full Text] [Related]
5. Lipid screening and cardiovascular health in childhood.
Daniels SR; Greer FR;
Pediatrics; 2008 Jul; 122(1):198-208. PubMed ID: 18596007
[TBL] [Abstract][Full Text] [Related]
6. Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome.
Adiels M; Olofsson SO; Taskinen MR; Borén J
Arterioscler Thromb Vasc Biol; 2008 Jul; 28(7):1225-36. PubMed ID: 18565848
[TBL] [Abstract][Full Text] [Related]
7. Statin-fibrate combination therapy.
Feeman WE
Am J Cardiol; 2008 May; 101(10):1521. PubMed ID: 18471475
[No Abstract] [Full Text] [Related]
8. On the road to better dyslipidemia outcomes.
Hughes S
Nurse Pract; 2009 Feb; 34(2):14-21; quiz 22. PubMed ID: 19155874
[No Abstract] [Full Text] [Related]
9. Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.
Fazio S
Clin Ther; 2008 Feb; 30(2):294-306. PubMed ID: 18343268
[TBL] [Abstract][Full Text] [Related]
10. Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.
Athyros VG; Kakafika AI; Karagiannis A; Mikhailidis DP
Am J Cardiol; 2008 Jun; 101(11):1679-80. PubMed ID: 18489951
[No Abstract] [Full Text] [Related]
11. Optimal management of persistent mixed dyslipidemia after statin initiation warrants combination therapy.
Boden WE; McGovern ME
Am J Cardiol; 2009 Dec; 104(12):1695-6. PubMed ID: 19962477
[No Abstract] [Full Text] [Related]
12. The Residual Risk Reduction Initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia.
Fruchart JC; Sacks F; Hermans MP; Assmann G; Brown WV; Ceska R; Chapman MJ; Dodson PM; Fioretto P; Ginsberg HN; Kadowaki T; Lablanche JM; Marx N; Plutzky J; Reiner Z; Rosenson RS; Staels B; Stock JK; Sy R; Wanner C; Zambon A; Zimmet P
Am J Cardiol; 2008 Nov; 102(10 Suppl):1K-34K. PubMed ID: 19068318
[TBL] [Abstract][Full Text] [Related]
13. Dyslipidemia and lipid-lowering therapy in the elderly.
Deedwania P; Volkova N
Expert Rev Cardiovasc Ther; 2005 May; 3(3):453-63. PubMed ID: 15889973
[TBL] [Abstract][Full Text] [Related]
14. Lipid management in chronic kidney disease, hemodialysis, and transplantation.
Montague T; Murphy B
Endocrinol Metab Clin North Am; 2009 Mar; 38(1):223-34. PubMed ID: 19217521
[TBL] [Abstract][Full Text] [Related]
15. Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.
Cardiovasc J Afr; 2009; 20(1):73-4. PubMed ID: 19287821
[No Abstract] [Full Text] [Related]
16. Managing dyslipidemia in chronic kidney disease.
Harper CR; Jacobson TA
J Am Coll Cardiol; 2008 Jun; 51(25):2375-84. PubMed ID: 18565393
[TBL] [Abstract][Full Text] [Related]
17. The appropriateness of nicotinic acid derivative use in patients with the metabolic syndrome: insights from the ARBITER 2 study.
Al-Shaer MH; Jerome WP
Am J Cardiol; 2006 Jul; 98(2):275-6. PubMed ID: 16828609
[No Abstract] [Full Text] [Related]
18. Fibrates and future PPARalpha agonists in the treatment of cardiovascular disease.
Staels B; Maes M; Zambon A
Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):542-53. PubMed ID: 18628776
[TBL] [Abstract][Full Text] [Related]
19. Is lipid management effective for all stages of CKD?
Ku E; Campese V
Blood Purif; 2013; 35(1-3):26-30. PubMed ID: 23343543
[TBL] [Abstract][Full Text] [Related]
20. Management of lipid abnormalities associated with end-stage renal disease.
Liu J; Kalantarinia K; Rosner MH
Semin Dial; 2006; 19(5):391-401. PubMed ID: 16970739
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
